BELITE BIO's pre-market share price fell 10.6% as the US Food and Drug Administration extended its review of eye medication.

Zhitongcaijing · 1d ago
BELITE BIO's pre-market share price fell 10.6% as the US Food and Drug Administration extended its review of eye medication.